Skip to main content

Dermatology Topic Center

News
03/14/2025
Individuals with vitiligo have an increased risk of major cardiovascular events, including stroke and venous thromboembolism, according to researchers.
Individuals with vitiligo have an increased risk of major cardiovascular events, including stroke and venous thromboembolism, according to researchers.
Individuals with vitiligo have...
03/14/2025
First Report Managed Care
News
02/18/2025
A new artificial intelligence (AI) algorithm has demonstrated high accuracy in assessing facial vitiligo, offering a faster and more objective method for evaluating disease severity and treatment response, according to a study published in...
A new artificial intelligence (AI) algorithm has demonstrated high accuracy in assessing facial vitiligo, offering a faster and more objective method for evaluating disease severity and treatment response, according to a study published in...
A new artificial intelligence...
02/18/2025
First Report Managed Care
News
02/10/2025
The use of ruxolitinib cream for atopic dermatitis shows promise in decreasing the need for other treatments, with reductions in oral corticosteroid use observed in some patients.
The use of ruxolitinib cream for atopic dermatitis shows promise in decreasing the need for other treatments, with reductions in oral corticosteroid use observed in some patients.
The use of ruxolitinib cream for...
02/10/2025
First Report Managed Care
News
01/13/2025
Patients with vitiligo in the US face significantly higher health care costs and resource utilization compared with the general population, according to a study published in the Journal of Investigative Dermatology.
Patients with vitiligo in the US face significantly higher health care costs and resource utilization compared with the general population, according to a study published in the Journal of Investigative Dermatology.
Patients with vitiligo in the US...
01/13/2025
First Report Managed Care
Conference Coverage
04/11/2024
An educational initiative aiming to improve access to high-quality care for individuals with atopic dermatitis by expanding managed care professionals' understanding of this condition will be presented at AMCP 2024.
An educational initiative aiming to improve access to high-quality care for individuals with atopic dermatitis by expanding managed care professionals' understanding of this condition will be presented at AMCP 2024.
An educational initiative aiming...
04/11/2024
First Report Managed Care
News
12/21/2023
"This study is necessary to allow physicians, patients, and health systems to make informed decisions regarding cost-efficacy for a variety of treatment options," said researchers.
"This study is necessary to allow physicians, patients, and health systems to make informed decisions regarding cost-efficacy for a variety of treatment options," said researchers.
"This study is necessary to...
12/21/2023
First Report Managed Care
Commentary
12/20/2023
Clinicians should consider both the physical and psychological aspects of living with vitiligo and implement measures to identify and efficaciously address them, which can improve patient adherence, clinical outcomes, patient well-being, and...
Clinicians should consider both the physical and psychological aspects of living with vitiligo and implement measures to identify and efficaciously address them, which can improve patient adherence, clinical outcomes, patient well-being, and...
Clinicians should consider both...
12/20/2023
First Report Managed Care
Commentary
12/14/2023
While the majority of Janus kinase inhibitors (JAKs) are available in oral formulations, in July 2022, the FDA approved ruxolitinib cream 1.5% as the only topical formulation of a selective JAK (JAK1/JAK2) inhibitor approved in the US,...
While the majority of Janus kinase inhibitors (JAKs) are available in oral formulations, in July 2022, the FDA approved ruxolitinib cream 1.5% as the only topical formulation of a selective JAK (JAK1/JAK2) inhibitor approved in the US,...
While the majority of Janus...
12/14/2023
First Report Managed Care
Commentary
11/20/2023
Since nonsegmental vitiligo is the most common type of vitiligo, the availability of the targeted therapy, Opzelura (topical ruxolitinib) cream, has the potential to help many patients living with vitiligo when appropriate. Improving access...
Since nonsegmental vitiligo is the most common type of vitiligo, the availability of the targeted therapy, Opzelura (topical ruxolitinib) cream, has the potential to help many patients living with vitiligo when appropriate. Improving access...
Since nonsegmental vitiligo is...
11/20/2023
First Report Managed Care
Commentary
11/06/2023
The findings from this study reveal that up to 50% of children and adolescents with vitiligo remained undiagnosed, which highlights the need to expand awareness about this dermatological condition, the two most common types, the need for...
The findings from this study reveal that up to 50% of children and adolescents with vitiligo remained undiagnosed, which highlights the need to expand awareness about this dermatological condition, the two most common types, the need for...
The findings from this study...
11/06/2023
First Report Managed Care